A single-center, non-randomized, prospective observational, pilot study designed to determine what is the optimal number of pleural biopsies to take during pleuroscopy.
After enrollment, participants will undergo pleural biopsies via pleuroscopy. Specimens will be divided into three aliquots (1-3, 4-6, 7-10), which will be sent to pathology. A designated pathologist will evaluate the specimens in each aliquot to determine the number of biopsies required to reach a diagnosis and to obtain sufficient material for biomarker testing (when needed), and determine whether analysis of further aliquots is needed.
Study Type
OBSERVATIONAL
Enrollment
104
Mount Sinai Hospital
New York, New York, United States
Number of pleural biopsies to reach a diagnosis
The number of pleural biopsies needed to reach a diagnosis.
Time frame: At week 2 after pleuroscopy
Number of pleural biopsies required for comprehensive biomarker testing.
The number of biopsies required to obtain sufficient material for comprehensive biomarker testing.
Time frame: At week 4 after pleuroscopy
Number of complications
Number of complications related to the biopsy.
Time frame: At week 4 after pleuroscopy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.